Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
Wednesday, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) dengue vaccine received World Health Organization's (WHO) prequalification.
周三，武田药业有限公司（纽约证券交易所代码：TAK）的登革热疫苗获得了世界卫生组织（WHO）的资格预审。
TAK-003 is the second dengue vaccine to be prequalified by WHO.
TAK-003 是世卫组织通过资格预审的第二种登革热疫苗。
The prequalification makes it eligible for procurement by United Nations agencies like UNICEF and Pan American Health Organization (PAHO).
资格预审使其有资格被联合国儿童基金会和泛美卫生组织（PAHO）等联合国机构采购。
The vaccine, dubbed Qdenga, is approved in Indonesia, Brazil, the European Union (EU), Iceland, the U.K., Norway, and Lichtenstein.
这种名为Qdenga的疫苗已在印度尼西亚、巴西、欧盟（EU）、冰岛、英国、挪威和列支敦士登获得批准。
Developed by Takeda, it is a live-attenuated vaccine containing weakened versions of the four serotypes of the virus that cause dengue.
它由武田开发，是一种减毒活疫苗，含有导致登革热的四种血清型病毒的弱化版本。
WHO recommends using TAK-003 in children aged 6–16 in settings with high dengue burden and transmission intensity.
世卫组织建议在登革热负担和传播强度高的环境中对 6-16 岁的儿童使用 TAK-003。
Related: Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%.
相关： 日本武田制药概述了9亿美元的改革以促进增长，因为2023年利润下降了50％以上。
The vaccine should be administered in a 2-dose schedule with a 3-month interval between doses.
疫苗应按2剂时间表接种，每剂之间间隔3个月。
Following discussions with the FDA in July last year, Takeda voluntarily withdrew its marketing application for TAK-003, citing data collection issues.
在去年7月与美国食品药品管理局讨论后，武田以数据收集问题为由自愿撤回了 TAK-003 的上市申请。
The drugmaker said the future plan for the candidate, TAK-003, in the U.S. would be further evaluated, given the need for travelers and those living in dengue-endemic areas of the U.S., such as Puerto Rico.
这家制药商表示，鉴于旅行者和生活在波多黎各等美国登革热流行地区的人的需求，将进一步评估候选人 TAK-003 在美国的未来计划。
In February, Takeda and Biological E. Limited partnered to expedite the distribution of Qdenga. These vaccines will be available for government procurement in dengue-endemic countries by 2030.
2月，武田和生物E.Limited合作加快了Qdenga的分销。到2030年，这些疫苗将可供登革热流行国家的政府采购。
Biological E. plans to scale up to produce 50 million doses annually, supporting Takeda's goal of producing 100 million doses a year within the next decade. This partnership will leverage Takeda's existing manufacturing in Singen, Germany, and its collaboration with IDT Biologika GmbH.
Biological E. 计划扩大规模，每年生产5000万剂，以支持武田在未来十年内每年生产1亿剂的目标。该合作伙伴关系将利用武田在德国辛根的现有生产基地及其与IDT Biologika GmbH的合作。
The WHO prequalification list also includes the CYD-TDV vaccine against dengue developed by Sanofi SA (NASDAQ:SNY).
世卫组织资格预审清单还包括赛诺菲公司（纳斯达克股票代码：SNY）开发的针对登革热的CYD-TDV疫苗。
Dengue is a vector-borne disease transmitted by the bite of an infected mosquito.
登革热是一种媒介传播的疾病，由受感染的蚊子叮咬传播。
It is estimated that over 100-400 million cases of dengue occur worldwide each year and that 3.8 billion people live in dengue-endemic countries, most of which are in Asia, Africa, and the Americas.
据估计，全球每年发生超过1亿至4亿例登革热病例，38亿人生活在登革热流行国家，其中大多数在亚洲、非洲和美洲。
The largest number of dengue cases reported was in 2023, with the WHO Region of the Americas reporting 4.5 million cases and 2300 deaths.
报告的登革热病例最多是在2023年，世卫组织美洲区域报告了450万例病例和2300例死亡。
Price Action: TAK shares are trading at $13.45 at last check Wednesday.
价格走势：在周三最后一次检查时，TAK股票的交易价格为13.45美元。
Photo by Wolfgang Hasselmann on Unsplash
沃尔夫冈·哈塞尔曼在 Unsplash 上拍摄的照片